drugset / Trial / NCT01421563

Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male Volunteers

NCT01421563

Phase 1 Completed 36 enrolled Alvogen Korea
RandomizedCrossoverOpen-label

Summary

The purpose of this study is compare the safety and pharmacokinetic characteristics of DP-R202 (Sarpogrelate HCl 300mg, qd) with those of Anplag (Sarpogrelate HCl 100mg, tid) after oral administration in healthy male volunteers.

Timeline

Start
2011-02
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarpogrelate Small molecule 100 mg Oral
Subject Sarpogrelate Small molecule 300 mg Oral

Indications

No indication recorded.